Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| ISX | Change of Financial Year End Date to 31 December | 24/04/18 | ||
| ISX | Ceasing to be a substantial holder | 20/04/18 | ||
| ISX | AMEX and ISXPay execute aggregator agreement | PRICE SENSITIVE | 28/03/18 | |
| ISX | XM Chinese eKYC via Paydentity | 20/03/18 | ||
| ISX | First European Based Merchant Transacting | 07/03/18 | ||
| ISX | Appendix 3B | 05/03/18 | ||
| ISX | Half Yearly Report and Accounts | PRICE SENSITIVE | 28/02/18 | |
| ISX | Four Major EEA/EU based merchants Contracted | PRICE SENSITIVE | 26/02/18 | |
| ISX | Poli Payments Integration with Paydentity | 15/12/17 | ||
| ISX Change of Financial Year End Date to 31 December | |||
| 24/04/18 | |||
| ISX Ceasing to be a substantial holder | |||
| 20/04/18 | |||
| ISX AMEX and ISXPay execute aggregator agreement | |||
| 28/03/18 | PRICE SENSITIVE | ||
| ISX XM Chinese eKYC via Paydentity | |||
| 20/03/18 | |||
| ISX First European Based Merchant Transacting | |||
| 07/03/18 | |||
| ISX Appendix 3B | |||
| 05/03/18 | |||
| ISX Half Yearly Report and Accounts | |||
| 28/02/18 | PRICE SENSITIVE | ||
| ISX Four Major EEA/EU based merchants Contracted | |||
| 26/02/18 | PRICE SENSITIVE | ||
| ISX Poli Payments Integration with Paydentity | |||
| 15/12/17 | |||
